+351 211 369 829 
Our approach
New in vitro diagnostics medical devices are essential in oncology to improve early detection, diagnosis, and treatment of cancer, ultimately leading to better patient outcomes. Finding biomarkers that are clinically relevant and effective in a real-world setting is a challenging process that requires rigorous testing and validation. Deploying them in a usable, validated and cost-effective format is a challenge on its own.
At Ophiomics we developed a unique approach to biomarker discovery and development centred around addressing strong clinical questions and minimising technical, clinical, and commercial uncertainties, enabling us to maximize the chances of bringing impactful products to market and positively impacting patients’ lives. We conceptualise our approach in three stages, as illustrated below.
Novel solutions for unmet clinical needs
We are an innovation-driven company developing novel diagnostics-directed technologies (see here for our Dx technology development) and Dx precision oncology solutions. On the latter we discover feasible biomarkers using our tried and tested bioinformatics data-mining pipeline, harnessing large volumes of omics data. Our focus are nuclei-acid-based biomarkers, including fragmented nuclei acids from liquid biopsies or FFPE tissues. We transform statistical signals into predictive algorithms using our expertise in Machine Learning. The output of this stage are product-prototypes, including a biomarker-based decision algorithm with well-defined predictive variables, paired with a laboratory assay design, and respective proof of concept results (TRL4).
-
Physicians and Scientists
Concerned about unmet clinical needs that would benefit from a biomarker-based decision.
-
Companies and Clinical Teams
Requiring large-scale data analysis to identify biomarkers able to stratify groups of patients, for example within clinical trials.
Transforming discoveries into market-ready IVD products
We use a standardised process to transform proof of concept-level essays into fully industrialised and market-ready products. We build on top of our proprietary technological platforms NOLO-Express and HYSEN-Liquid to develop full prototypes in as little as 6 weeks. Our product prototypes are developed in our ISO 13485 – certified pilot manufacturing facility, supported by our R&D laboratory in clinical validation studies.
-
Physicians and Scientists
Who wish to licence a discovery and collaborate with an industrial partner to develop a clinical product that can directly impact patients’ lives.
-
Companies and Clinical Teams
That already identified clinically relevant biomarkers for patient stratification and wish support in developing a companion diagnostic.
-
Tech Transfer offices
Who wish to engage an industrial partner to evaluate and licence biomarker/diagnostic algorithm discoveries from an Institutional portfolio.
Bringing meaningful products to market
We firmly believe that early commercial validation is critical for the success of any Dx product and aim to reduce the market uncertainty as early as possible. To this aim we devise strategies for early clinical prototyping of our products and seek direct market feedback through collaborative relationships with other companies, including Dx distributors.
-
Biotech/MedTech Companies
With products that can be synergistic with our portfolio and that wish to discuss possibilities of technical and/or commercial collaboration.
-
Distributors and Commercial Partners
With demonstrated access to relevant markets, that wish to partner with Ophiomics to commercialise one or more of our products.
Ophiomics Pipeline
 |
|||||||
|---|---|---|---|---|---|---|---|
| Clinical need | Product | Sample | Discover | Develop | Validate | Commercialise | |
| Liver cancer patient stratification for transplantation |  |
FFPE | |||||
| Diagnosis and prognosis of Barrett's Esophagus |  |
FFPE | |||||
| Liquid biopsy for ealy liver cancer detection in cirrhotic patients |  |
Blood | |||||
